Purdue Pharma's 'one-two' punch
The name “Sackler” adorns museums and art galleries around the world. But the family name has also become tainted by its association with the US opioid crisis, amid accusations that OxyContin, more th...
11 Sep 201821min
Following the cannabis money trail (encore episode)
Medical marijuana is legal in 21 countries. In Canada, residents expect they will be able to buy cannabis from dispensaries and pharmacies across the country later this year. Some analysts have valued...
4 Sep 201819min
Khosrowshahi's year at the wheel
A little more than a year ago, Uber's board was in search of a new chief executive. Co-founder Travis Kalanick had resigned from the top job amid allegations of a toxic and sexist company culture, and...
28 Aug 201819min
Digging into student debt
The amount of outstanding student debt in the US has hit a staggering $1.4tn, and many millennials say the education-related debt they've been saddled with has prevented them from doing things like bu...
21 Aug 201817min
Taking Tesla private
What is behind Elon Musk's plan to take the electric carmaker private, and who will provide the funding? The FT's Arash Massoudi explains the story that has unfolded since the chief executive posted h...
14 Aug 201819min
Tesla’s rough ride
Elon Musk's grand vision for the electric carmaker has drawn dedicated fans and followers. But Tesla has also tested the patience of customers and investors after a hit-and-miss on production targets ...
7 Aug 201818min
Private equity's debt mountain
Private equity has flooded the deal market in recent years, in part due to an era of cheap debt and fund managers on the hunt for greater investment returns. Firms are scooping up stakes in oil pipeli...
31 Jul 201820min
Taking a short break
Behind The Money is going on a short hiatus for the next few weeks. We'll be back on Tuesday 31 July with brand new episodes. In the meantime, send us an email to behindthemoney@ft.com if you have any...
3 Jul 20181min
